AAGP® May Extend the Promise of Transplanted Cells
The world of cell therapies holds amazing promise for improved treatments for a host of diseases, from cancer to autoimmune conditions and more. But cells can be delicate, vulnerable things. We believe AAGP® holds the potential to extend the survivability of cells used in cell transplantation, regenerative medicine, and other emerging technologies.
In fact, this anti-aging glycopeptide has already been shown to improve cell production yields, cell survival during storage, and cell viability during retrieval and recovery. At ProtoKinetix, we’re exploring the incredible possibilities AAGP® presents for the research and development of improved cell transplantation therapies.
The current limits of cell transplants
Cell transplantation is an important component to help patients with many different conditions, for example blood stem cells or immunotherapy cells for cancer patients to insulin producing cells for diabetes. Cells transplanted into the recipient face stress from the inflammation of the operation to the anti-rejection medicine used to keep the cells secured. Often stem cells are used in cell transplantation as a medical strategy to regenerate or rejuvenate diseased or damaged organs and tissues. The goal is to use the transplanted cells to treat, repair, heal, or otherwise support diseased or damaged tissue.
However, there are risks and limitations to cell transplantation that can affect the beneficial outcome.
Challenges of cell transplantation
- Preserving viability during manufacturing
- Enhancing storage and shelf life
- Improving cell yields
- Promoting cell survivability
- Improving functionality post-transplant
Cell transplant treatments
Currently, the harvest or manufacture of cells for transplantation, as well as the storage and transport of these materials, places the cell product at risk of degrading and losing viability and functionality.
Although methods have been developed and refined that afford a measure of protection, we believe there is extensive opportunity to improve the promise of these cells.
AAGP® as a potential solution
The anti-aging properties of AAGP® have the potential to greatly improve cell survivability — and therefore greatly improve human outcomes for cell transplantation.
With the protective qualities of AAGP® incorporated into these cell transplant technologies, we see the potential for improved cell production yields, advanced cell survival during storage, transport and transplant, and increased functionality post-graft. Early research into using AAGP® during islet cell transplantation has already yielded promising results.
ProtoKinetix research and studies
Read more about the results of our exploration into cell survivability using AAGP®.
Effect of AAGP® on preserving cell survival number in human and mouse neural stem cells during cryopreservation – View the research
Islet Transplantation Using PXX-001 –View the research
Cell transplants are a therapy with massive market implications. Currently, the market potential for bone marrow (stem cell) transplants alone is expected to reach $15 billion by 2027¹. Global stem cell transplant revenue generated over $9 billion in 2020², with projections calling for $18.4 billion in revenue by 2028³.
With the rapidly increasing incidence of blood cancers and autoimmune diseases driving demand for safe, effective cell transplant therapies, the compound annual growth rate for this market is projected to be 8.8% for the period between 2020 and 2027.
2020 Market Revenue:
2028 Projected Forecast:
Support our stem cell survivability research, while you support your own financial future. Contact your broker or reach out to our team at ProtoKinetix to learn about potential investment options.